Preventive Pharmacotherapy of Headache Disorders

by Olesen, Jes; Silberstein, Stephen D.; Tfelt-Hansen, Peter

• ISBN13: 9780198528449
• ISBN10: 0198528442
• Format: Hardcover
• Copyright: 2004-04-15
• Publisher: Oxford University Press

Summary

Most of the familiar headache drugs are used to stop a headache attack that is already in progress, or about to begin. However, there is now a growing body of research aimed at developing medications that can be taken on a regular basis to prevent headaches from starting. These drugs will be targetted at patients whose headaches are frequent or who get their headaches at predictable times. This book reviews the potential for prophylactic treatment of headache. It provides most of the existing evidence in the field of pharmaco-prophylaxis of migraine and other chronic headaches and may thus, serve as a platform for new initiatives in the field. The book reviews the research into the pharmacological mechanisms involved, the classes of drugs in development and the clinical trials methodology. The editors have gathered together the leading international experts to produce a book that will appeal to neurologists caring for headache patients, researchers in the field and those based in the pharmaceutical industry.

Table of Contents

Contributors	xi
Session I Methodology of prophylactic trials
1 Principles of preventive pharmacotherapy in primary headache	03	(7)
P.J. Goadsby
2 Methodology and implementation of systematic reviews	10	(13)
H.J. McQuay
3 Adverse events, equally important as efficacy as an outcome parameter?	23	(6)
D.I. Stenver
4 The methodology of prophylactic trials: discussion summary	29	(4)
P. Tfelt-Hansen
Session II Prophylactic drugs I
5 Key issues in the methodology of prophylactic migraine trials	33	(6)
P. Tfelt-Hansen
6 Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France	39	(5)
M. Lantéri-Minet, H. Alchaar, G. Besson, F. Billé-Turc, F. Brudon, A. Donnet, J. Valance, and J.L. Gastaut
7 Preventive treatment of migraine headache with rofecoxib	44	(6)
W. H. Visser, W. Malbecq, K. Strohmaier, C. Lines, and S. A. Reines
8 Prophylactic treatment and course of the disease in headache associated with sexual activity	50	(5)
A. Frese, K. Frese, S. Schwaag, A. Rahmann, I.-W. Husstedt, and S. Evers
9 Prophylactic drugs I: discussion summary	55
S.D. Silberstein
Session III Prophylactic drugs II
10 Prevention of migraine: beta-blockers and amine agonists: efficacy	59	(8)
H.-C. Diener and V. Limmroth
11 AEDs in migraine prevention	67	(12)
S.D. Silberstein
12 Mechanism(s) of action of the antiepileptic drugs valproic acid, gabapentin, and topiramate: implications for the prophylactic management of migraine	79	(10)
H.S. White
13 Experience with topiramate in patients with refractory migraine	89	(5)
J. Pascual, M. Sánchez del Rio, V. Mateos, J.M. Láinez J. Hernández-Gallego, R. Leira, and M.D. Jiménez
14 Topiramate in a selective group of therapy refractory headache patients	94	(4)
R.M. Agosti and S. Eugster
15 Prophylactic drugs II: discussion summary	98	(5)
J. Schoenen
Session IV Prophylactic drugs III
16 Efficacy of antidepressants in headache prophylaxis	103	(9)
L. Bendtsen
17 Antidepressants: mechanisms of action	112	(9)
E. Richelson
18 Other prophylactic anti-migraine agents: riboflavin, feverfew, magnesium, Botulinum toxin, and calcium antagonists	121	(13)
J. Schoenen, L. Di Clemente, and G. Coppola
19 Treatment of chronic tension-type headache with mirtazapine	134	(4)
I.B. Kulaksizoglu, S. Cakir, and M. Ertas
20 Botulinum toxin type A in the treatment of refractory headache	138	(4)
S.J. Tepper, M.E. Bigal, F.D. Sheftell, and A.M. Rapoport
21 Botulinum toxin A in the prophylaxis of migraine-a double-blind, placebo-controlled, randomized study comparing frontal and cervical injection	142	(7)
S. Schwaag, A. Rahmann, A. Frese, I.-W. Husstedt, J. Vollmer-Haase, and S. Evers
22 Description of a prospective, multicenter observational study of headache treatment with botulinum toxin type A: the program to assess treatment strategies (PATSTM) registry	149	(9)
S.D. Silberstein, M.A. Stiles, C. Gebeline-Myers, and K.C. Bradley
23 Mechanisms of the antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing	158	(5)
M. Cui and K.R. Aoki
24 Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment	163	(5)
G. Coloprisco, S. De Filippis, P.G. Santi, G. Fiore, A. Radio, and P. Martelletti
25 Prophylactic treatment of migraine with lomerizine hydrochloride	168	(7)
Y. Hibi, H. Igarashi, and F. Sakai
26 Prophylactic drugs III: discussion summary	175	(4)
P.J. Goadsby
Session V New targets I
27 Antagonizing peripheral sensitization in migraine	179	(10)
S. Bolton and C. O'Shaughnessy
28 New possibilities for antimigraine therapy via 5-HT receptors?	189	(5)
R.G. Hill, M.J. Cumberbatch, and D.J. Williamson
29 Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine	194	(5)
B. Schaerlinger, P. Hickel, N. Etienne, and L. Maroteaux
30 Migraine prophylaxis with drugs influencing the angiotensin system	199	(6)
L.J. Stovner, E. Tronvik, H. Schrader, G. Helde, T. Sand, and G. Bovim
31 Naratriptan in the preventive treatment of refractory chronic migraine	205	(7)
A.M. Rapoport, M.E. Biga1, S.J. Tepper, and F.D. Sheftell
32 PROMISE study (PROphylaxis of Migraine with SEglor®)	212	(5)
A. Pradalier, N. Lanteri-Minet, Ch Lucas, and G. Geraud
33 Serotonin receptors and migraine prophylaxis-the case of dihydroergotamine	217	(7)
M. Hamon, S. Bourgoin, and L. Lanfumey
34 What is the mechanism of action of ACE inhibitors in migraine prophylaxis?	224	(4)
R. Peatfield
35 Triptans with methysergide	228	(1)
D. Valade
36 New targets I: discussion summary	229	(6)
J. Olesen
Session VI New targets II
37 Nitric oxide and its signalling pathways: a rich source of potential targets for migraine therapy	235	(11)
P.J.L.M. Strijbos and A.A. Parsons
38 Calcitonin gene-related peptide and migraine	246	(10)
H. Doods, S. Just, M. Schindler, W. Eberlein, W. Engel, K. Rudolf, and K. Arndt
39 Phosphodiesterases, cyclic nucleotides, and their role in migraine	256	(10)
C. Kruuse and J. A. Beavo
40 The prostaglandin-El-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia	266	(5)
S. Evers, A. Frese, S. Schwaag, R. Lüttmann, and I.-W. Husstedt
41 New targets II: discussion summary	271	(2)
R.G. Hill
Index	273